Prognostic Value of Blood Serum Content of Soluble CD50 and CD54 Molecules in Patients with Uterine and Cervical Cancer

The aim of the investigation was to reveal the correlation of blood serum content of soluble CD50 and CD54 molecules in patients suffering from uterine and cervical cancer with oncological pathology localization, histological structure of the tumor, degree of tumor differentiation, and the extent of tumor invasion in the surrounding tissues, and to evaluate its significance for the disease prognosis.

Materials and Methods. 83 patients aged 31 to 79 years were under observation. The serum level of soluble CD50 and CD54 molecules was determined by enzyme immunoassay with mouse monoclonal antibodies. Blood from the cubital vein was taken to obtain serum samples.

Results. The development of malignant pathology of uterine and cervix was found to be accompanied by alteration of the serum level of CD50 and CD54 molecules. This alteration depends on oncological pathology localization, histological structure of the tumor, degree of tumor differentiation, and the extent of tumor invasion in the surrounding tissues. The serum level of soluble CD50 and oligomeric fractions of CD54 molecules was proved to decrease in patients with a worse prognosis. The initial concentration of soluble CD50 and CD54 molecules in the preoperative period can be considered an additional test allowing prediction of the disease progression in patients with uterine tumors.

1. Novikov V.V., Alyasova A.V., Utkin О.V., Lyutina E.V., Novikov D.V., Varshavskaya L.V. The soluble antigens CD38 and CD95 at breast cancer. Rossiyskiy bioterapevticheskiy zhurnal 2005; 4(3): 46–51.
2. Novikov V.V., Egorova N.I., Kurnikov G.Y., Evsegneeva I.V., Baryshnikov A.Y., Karaulov A.V. Serum levels of soluble HLA and IL-2R molecules in patients with urogenital chlamydia infection. Adv Exp Med Biol 2007; 601: 285–289, http://dx.doi.org/10.1007/978-0-387-72005-0_30.
3. Khudiakova N.E., Novikov V.V., Kravchenko G.A., Ivanova N.I., Ptitsyna I.S., Nosov N.N. Soluble HLA class I and HLA class II antigens in the blood of HIV infected patients. Zh Mikrobiol Epidemiol Immunobiol 2004; 1: 42–45.
4. Lebedev M.J., Egorova N.I., Sholkina M.N., Vilkov S.A., Baryshnikov A.J., Novikov V.V. Serum levels of different forms of soluble CD38 antigen in burned patients. Burns 2004; 30(6): 552–556, http://dx.doi.org/10.1016/j.burns.2004.01.029.
5. Evans B.J., McDowall A., Taylor P.C., Hogg N., Haskard D.O., Landis R.C. Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. Blood 2006; 107(9): 3593–3599, http://dx.doi.org/10.1182/blood-2005-09-3695.
6. Novikov V.V., Gostuzhova E.A., Karaulov A.V., Samoylova O.S., Babaev A.A., Volkova S.A., Grishunina N.E., Novikov D.V., Kokushkov D.V., Baryshnikov A.Yu. The state of the pool of soluble forms of immune cells membrane antigens at acute leukemia. Rossiyskiy immunologicheskiy zhurnal 2009; 3(2(12)): 164–170.
7. Kravchenko G.A., Novikov D.V., Ptitsyna Yu.S., Novikov V.V. Soluble immune cell membrane antigen levels in serum of carriers of viral hepatitis G markers. Voprosy virusologii 2005; 50(5): 19–22.
8. Roland C.L., Harken A.H., Sarr M.G., Barnett C.C. Jr. ICAM-1 expression determines malignant potential of cancer. Surgery 2007; 141(6): 705–707, http://dx.doi.org/10.1016/j.surg.2007.01.016.
9. Sheikh N.A., Jones L.A. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 2008; 57(9): 1381–1390, http://dx.doi.org/10.1007/s00262-008-0474-9.
10. Babaev A.A., Knyazev D.I., Kravchenko G.A., Manakova E.A., Novikova D.V., Pegov R.G., Baryshnikov A.Yu., Karaulov A.V., Novikov V.V. Soluble oligomers of CD50 and CD18 adhesion molecules in human sera. Immunologiya 2011; 32(2): 69–71.
11. Kubysheva N.I., Postnikova L.B., Presnyakova N.B., Korolyova V.V., Kokushkov D.V., Karaulov A.V., Novikov V.V. Soluble ICAM-1 and ICAM-3 antigens in chronic obstructive pulmonary disease. Immunologiya 2009; 30(1): 55–56.
12. Mamaeva М.Е., Shumilova S.V., Kazatskaya Zh.А., Khazov М.V., Novikov V.V., Alyasova А.V. The content of soluble HLA class I and HLA-DR molecules in serum in patients with uterine cervix and body pathology. Sovremennye tehnologii v medicine 2014; 6(2): 85–92.
13. Mamaeva М.Е., Novikov D.V., Alyasova А.V., Kopylova G.Е., Khazov М.V., Karaulov А.V., Novikov V.V. The content of oligomeric and total fractions of soluble CD38 molecules in blood serum of patients with hysteromyoma. Sovremennye tehnologii v medicine 2014; 6(4): 140–144.
14. Pegov R.G., Alyasova A.V., Novikov V.V. The soluble antigens CD38 and CD50 at lung cancer. Rossiyskiy bioterapevticheskiy zhurnal 2006; 5(1): 9–10.
15. Varshavskaya L.V., Alyasova A.V., Baryshnikov A.Yu., Novikov V.V. Membrane and soluble forms of CD50 (ICAM-3)-antigen at breast cancer. Rossiyskiy bioterapevticheskiy zhurnal 2004; 3(2): 17–18.
16. Gu X., Ma C., Yuan D., Song Y. Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. Transl Lung Cancer Res 2012; 1(1): 36–44, http://dx.doi.org/10.3978/j.issn.2218-6751.08.01.
17. Mantur M., Snarska J., Koper O., Dziecioł J., Płonski A., Lemancewicz D. Serum sICAM, sVCAM and sE-selectin levels in colorectal cancer patients. Folia Histochem Cytobiol 2009; 47(4): 621–625, http://dx.doi.org/10.2478/v10042-009-0077-0.
18. Lawson C., Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009; 61(1): 22–32, http://dx.doi.org/10.1016/s1734-1140(09)70004-0.
19. Korovushkina K.A., Babaev A.A., Kotelnickova T.V., Kontorshickova E.Yu., Karaulov A.V., Baryshnickov A.Yu., Novickov V.V. Role of the soluble differentiated molecule structural and functional forms in differential diagnosis of the uterus myoma and endometrium cancer. Sovremennye tehnologii v medicine 2010; 2: 53–57.

Mamaeva M.E., Alyasova А.V., Shumilova S.V., Kazatskaya Zh.А., Khazov M.V., Churkina N.N., Novikov V.V. Prognostic Value of Blood Serum Content of Soluble CD50 and CD54 Molecules in Patients with Uterine and Cervical Cancer. Sovremennye tehnologii v medicine 2015; 7(4): 141, https://doi.org/10.17691/stm2015.7.4.19